Infigo Diagnostics Ltd

Infigo’s platform technology, the MIPdxTM, offers the healthcare and diagnostic industry a solution that obliterates the barriers in molecular diagnostics in regard to the capability of rapidly quantifying biological and small molecular markers at all clinical settings. Markers in need of quantification such as cardiovascular biomarkers, companion diagnostics, personalized medicine and metabolic markers are mostly limited to laboratory settings which produce at most times imprecise results. These markers, and an endless amount of diagnostic products, can be quantified with Infigo's MIPdxTM platform technology at home, point of care and laboratory settings.